CTLA4 阻断在间皮瘤中的应用：最终成为细胞毒/靶向治疗的竞争策略？
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
机构信息
Immunoterapia Oncologica, Dipartimento di Oncologia Medica, Istituto Toscano Tumori, Azienda Ospedaliera Universitaria Senese, Viale Mario Bracci n. 16, 53100, Siena, Italy,
出版信息
Cancer Immunol Immunother. 2015 Jan;64(1):105-12. doi: 10.1007/s00262-014-1609-9. Epub 2014 Sep 19.
Abstract
No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.
摘要
二线治疗并不能显著延长有高度未满足医疗需求的恶性间皮瘤患者的生存时间。在这里，我们评论了抗 CTLA4 单克隆抗体（mAb）tremelimumab 对难治性恶性间皮瘤患者的细胞毒性 T 淋巴细胞相关蛋白（CTLA）4 阻断的治疗潜力。我们还重点讨论了在免疫调节 mAb 治疗过程中进行准确肿瘤评估的关键作用。最后，将讨论在这种致命疾病中使用潜在有效、第二代检查点（s）抑制 mAb 以及未来的联合治疗策略。
相似文献
1
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Cancer Immunol Immunother. 2015 Jan;64(1):105-12. doi: 10.1007/s00262-014-1609-9. Epub 2014 Sep 19.
2
Tremelimumab for the treatment of malignant mesothelioma.
Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515.
3
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.
4
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Int J Cancer. 2019 Oct 15;145(8):2238-2248. doi: 10.1002/ijc.32363. Epub 2019 May 13.
5
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.
6
Anti-CTLA-4 therapy for malignant mesothelioma.
Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123.
7
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
Toxins (Basel). 2018 Nov 14;10(11):470. doi: 10.3390/toxins10110470.
8
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Lancet Respir Med. 2015 Apr;3(4):301-9. doi: 10.1016/S2213-2600(15)00092-2. Epub 2015 Mar 26.
9
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
Semin Oncol. 2010 Oct;37(5):460-7. doi: 10.1053/j.seminoncol.2010.09.006.
10
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
Cancer Treat Rev. 2015 Dec;41(10):914-24. doi: 10.1016/j.ctrv.2015.09.006. Epub 2015 Sep 28.
引用本文的文献
1
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.
Adv Ther. 2021 Jul;38(7):3674-3693. doi: 10.1007/s12325-021-01796-6. Epub 2021 Jun 8.
2
Immunotherapy in Malignant Pleural Mesothelioma.
Front Oncol. 2020 Feb 21;10:187. doi: 10.3389/fonc.2020.00187. eCollection 2020.
3
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.
Cancer Immunol Immunother. 2018 Aug;67(8):1317-1324. doi: 10.1007/s00262-018-2191-3. Epub 2018 Jun 26.
4
New horizons from immunotherapy in malignant pleural mesothelioma.
J Thorac Dis. 2018 Jan;10(Suppl 2):S322-S332. doi: 10.21037/jtd.2017.12.88.
5
Enhancement of antitumor immunity by combination of anti-CTLA-4 antibody and radioimmunotherapy through the suppression of Tregs.
Oncol Lett. 2017 May;13(5):3781-3786. doi: 10.3892/ol.2017.5933. Epub 2017 Mar 28.
6
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.
7
Tremelimumab: research and clinical development.
Onco Targets Ther. 2016 Mar 23;9:1767-76. doi: 10.2147/OTT.S65802. eCollection 2016.
8
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Ther Adv Med Oncol. 2016 Jan;8(1):4-31. doi: 10.1177/1758834015615514.
本文引用的文献
1
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
Oncoimmunology. 2014 Jan 1;3(1):e27482. doi: 10.4161/onci.27482. Epub 2014 Jan 3.
2
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
3
Epigenetic drugs as immunomodulators for combination therapies in solid tumors.
Pharmacol Ther. 2014 Jun;142(3):339-50. doi: 10.1016/j.pharmthera.2013.12.015. Epub 2013 Dec 30.
4
Biomarkers for immune checkpoint inhibitors--authors' reply.
Lancet Oncol. 2014 Jan;15(1):e1-2. doi: 10.1016/S1470-2045(13)70573-4.
5
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 2013 Oct 23;5(208):208ra147. doi: 10.1126/scitranslmed.3006941.
6
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.
7
Immunotherapy and the concept of a clinical cure.
Eur J Cancer. 2013 Sep;49(14):2965-7. doi: 10.1016/j.ejca.2013.06.019. Epub 2013 Jul 25.
8
New checkpoint inhibitors ride the immunotherapy tsunami.
Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.
9
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.
Thorax. 2014 Feb;69(2):194-7. doi: 10.1136/thoraxjnl-2013-203846. Epub 2013 Jun 12.
10
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
Zotero 插件